Comparative Pharmacology
Head-to-head clinical analysis: BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus TETRACYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISMUTH SUBCITRATE POTASSIUM METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus TETRACYN.
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE vs TETRACYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bismuth subcitrate potassium forms a protective coating on gastric mucosa, binds to bile acids, and has antibacterial activity against Helicobacter pylori. Metronidazole inhibits nucleic acid synthesis by disrupting bacterial DNA, while tetracycline hydrochloride inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the A site.
For Helicobacter pylori eradication: 1 tablet (bismuth subcitrate potassium 140 mg, metronidazole 125 mg, tetracycline hydrochloride 125 mg) orally 4 times daily (with meals and at bedtime) for 14 days, plus a proton pump inhibitor.
250–500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 6–12 hours (administer slow IV).
None Documented
None Documented
Metronidazole: 8 hours (range 6-10), prolonged in hepatic impairment; Tetracycline: 6-11 hours (normal renal function), 57-120 hours in anuria; Bismuth subcitrate: negligible systemic absorption, elimination follows transit (~24-72 hours).
Terminal elimination half-life: 6-8 hours in normal renal function; prolonged to 18-30 hours in severe renal impairment (CrCl <30 mL/min); dosing adjustment required.
Metronidazole: 60-80% renal (as unchanged drug and metabolites), 6-15% fecal; Tetracycline: 60% renal (glomerular filtration), 40% fecal (biliary and unabsorbed); Bismuth subcitrate: >99% fecal as insoluble bismuth sulfide.
Renal (glomerular filtration): 60% unchanged in urine; biliary/fecal: 40% as active drug and metabolites; enterohepatic recirculation occurs.
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic